Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
November 28, 2025 | obesity
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected on the latest research, the shifting clinical landscape, and how collaboration across disciplines can improve care for people living with obesity.
In this post-event roundtable, Matt Wadyka (Inizio Medical), Alexis Cogswell (Real-World iNSIGHTS, Inizio Medical), Varun Renjen MD (Putnam, part of Inizio Advisory), and Elaine Ferguson (Inizio Medical) share their perspectives on what’s shaping the next phase of obesity care.
Putting patients at the center of decision-making
Matt Wadyka, Senior Vice President at Inizio Medical, reflected on how the voice of the person living with obesity is becoming central to clinical progress.
“What I’m most excited about is the evolving role of the patient in their own decision-making when it comes to healthcare with obesity,” said Matt. “With multidisciplinary teams in attendance, it’s clear that keeping the patient at the center is foundational to making the right decisions for the right person at the right time.”
He also noted that the pace of innovation is accelerating rapidly, with new entrants transforming the scientific dialogue.
“For a long time, there were only a couple of major players in the space,” he explained. “Now, with so many new companies and modalities, we’re seeing an explosion of new science that’s changing how we think about treatment, and even how we define the disease itself.”
Redefining obesity through data and real-world insight
Alexis Cogswell, Vice President, Real-World iNSIGHTS, Inizio Medical, emphasized that the shift toward recognizing obesity as a chronic, multifactorial condition is reshaping how data is applied in practice.
“At Real-World iNSIGHTS, we’re really interested in understanding how new data are being taken into clinical practice by providers globally,” said Alexis. “The reframing of obesity as a chronic condition makes perfect sense given the breadth of GLP-1 approvals in recent years.”
She also previewed the upcoming Clinical Excellence Summit in Obesity, taking place next April, which will explore how groundbreaking research presented at ObesityWeek® is influencing clinical decisions.
“We’ll be looking at how these treatments are being used for the people who need them most, with conversations that include patients, providers and payers.”
Redefining the science of obesity
For Varun Renjen MD, Partner at Putnam (part of Inizio Advisory), one of the biggest scientific shifts is the very definition of obesity itself.
“It’s not just about reducing weight from a BMI perspective,” said Varun. “Obesity is a complex heterogenous physiological process that affects multiple organs – the heart, kidney, lungs, liver, and even the brain across the same pathway. There is a clear pathological process in obesity that affects the whole body”
He described the meeting as a sign that the field is entering a new era of treating obesity including precision and personalization.
“We’re at the beginning of a true scientific revolution, redefining what obesity is as potentially cardiometabolic dysfunction, how it’s treated, and how care is customized across the patient journey. Whether it’s moving between therapies, mechanisms, modalities or quality of weight loss, we’re learning how to adapt treatments as people progress with GLP-1s and beyond. If in the past cancer was treated with chemotherapy and has rapidly progressed to different modalities and segments; that is where we are going with obesity.”
From weight loss to whole-body health
Elaine Ferguson, Global President, Inizio Medical, highlighted the remarkable diversity of science showcased this year.
“There’s been a real breadth of science this week, and the biggest impact for me is seeing all the different pathways and mechanisms under investigation,” said Elaine. “We’re seeing ambitious trial designs and outcomes that go far beyond weight loss, looking at organ protection and whole-body health.”
She also underscored the importance of hearing directly from people living with obesity at the congress.
“It’s been inspiring to hear their experiences – not just in terms of physical changes, but the overall improvements in health, energy, and quality of life.”
Looking ahead
Reflecting on the week, Matt summed up the opportunity ahead:
“Right now, there’s a big emphasis on insights. Next, it’ll be about data, and then the focus will turn to access and affordability. This is a pivotal moment to be part of the obesity field.”
From redefining the science to centering lived experience, the energy and collaboration seen at ObesityWeek® 2025 reaffirm that the field is moving fast, and Inizio is proud to be part of shaping its future.
Discover more about how Inizio is driving innovation across the obesity landscape
This content was provided by Inizio
Company Details
Latest Content from Inizio
Research Partnership launches new patient report – Living with Lupus (SLE)
Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US and European markets. The report will consist of 30-minute face to face interviews with a...
Webinar: Ensuring an Actionable Segmentation
A segmentation study comes with high visibility and high stakes across your marketing and sales organisations. Ensuring that a segmentation is actionable is a consistent issue, particularly when stakeholders with multiple...
Interactive infographic: LATAM
An overview of the six most-commonly researched, largest pharma markets in Latin America
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies,...
Case Study: Using ‘Journey to the Future’ projective techniques to understand evolving customer expectations
Our client was developing a portfolio of innovative treatments and was in the process of recruiting a sales force to support the promotion of this portfolio. Research was required to...
Pegasus scoops five ‘Consultancy’ wins, making 2016 a stellar year for the health comms consultancy
Pegasus, an Ashfield company, part of UDG Healthcare plc, last night scooped its fifth ‘consultancy’ award of the year at the PRCA Awards in London’s Park Lane where it secured...
Free Thinking – US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare
Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare
Pegasus crowned PR Week’s Specialist Consultancy of the Year, making a hat-trick of Consultancy wins in 2016!
Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have been crowned Specialist Consultancy of the Year at this week’s prestigious PR Week Awards. The accolade tops...
Therapy Watch market snapshots
Therapy Watch is a ‘real-time’ syndicated market tracking tool that provides marketing teams, brand managers and market researchers with strategic and tactical market information. Run entirely online to ensure speed,...
Case Study: Private market opportunity for a travel vaccine
Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. It was crucial to determine:Which markets had the highest potential to...